Free Trial

Corbus Pharmaceuticals (CRBP) Competitors

$45.02
+3.64 (+8.80%)
(As of 05/24/2024 ET)

CRBP vs. CELC, STTK, SLDB, IMMP, DNTH, COGT, WVE, ACRV, STOK, and PRQR

Should you be buying Corbus Pharmaceuticals stock or one of its competitors? The main competitors of Corbus Pharmaceuticals include Celcuity (CELC), Shattuck Labs (STTK), Solid Biosciences (SLDB), Immutep (IMMP), Dianthus Therapeutics (DNTH), Cogent Biosciences (COGT), Wave Life Sciences (WVE), Acrivon Therapeutics (ACRV), Stoke Therapeutics (STOK), and ProQR Therapeutics (PRQR). These companies are all part of the "medical" sector.

Corbus Pharmaceuticals vs.

Celcuity (NASDAQ:CELC) and Corbus Pharmaceuticals (NASDAQ:CRBP) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, community ranking, analyst recommendations, institutional ownership and risk.

In the previous week, Celcuity had 3 more articles in the media than Corbus Pharmaceuticals. MarketBeat recorded 10 mentions for Celcuity and 7 mentions for Corbus Pharmaceuticals. Celcuity's average media sentiment score of 0.52 beat Corbus Pharmaceuticals' score of 0.28 indicating that Corbus Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Celcuity
1 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Corbus Pharmaceuticals
0 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Corbus Pharmaceuticals received 104 more outperform votes than Celcuity when rated by MarketBeat users. However, 66.87% of users gave Celcuity an outperform vote while only 66.41% of users gave Corbus Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
CelcuityOutperform Votes
327
66.87%
Underperform Votes
162
33.13%
Corbus PharmaceuticalsOutperform Votes
431
66.41%
Underperform Votes
218
33.59%

Corbus Pharmaceuticals' return on equity of -61.66% beat Celcuity's return on equity.

Company Net Margins Return on Equity Return on Assets
CelcuityN/A -61.66% -43.51%
Corbus Pharmaceuticals N/A -135.17%-57.70%

63.3% of Celcuity shares are held by institutional investors. Comparatively, 64.6% of Corbus Pharmaceuticals shares are held by institutional investors. 24.3% of Celcuity shares are held by company insiders. Comparatively, 4.0% of Corbus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Corbus Pharmaceuticals has higher revenue and earnings than Celcuity. Corbus Pharmaceuticals is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CelcuityN/AN/A-$63.78M-$2.78-5.63
Corbus Pharmaceuticals$880K546.89-$44.60M-$6.96-6.47

Celcuity has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Corbus Pharmaceuticals has a beta of 2.46, indicating that its stock price is 146% more volatile than the S&P 500.

Celcuity presently has a consensus price target of $29.50, suggesting a potential upside of 88.62%. Corbus Pharmaceuticals has a consensus price target of $61.00, suggesting a potential upside of 35.50%. Given Corbus Pharmaceuticals' higher probable upside, equities research analysts plainly believe Celcuity is more favorable than Corbus Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celcuity
0 Sell rating(s)
0 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
3.00
Corbus Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00

Summary

Celcuity beats Corbus Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CRBP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CRBP vs. The Competition

MetricCorbus PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$481.26M$6.73B$5.19B$8.06B
Dividend YieldN/A2.67%2.83%3.93%
P/E Ratio-6.4716.54140.2917.24
Price / Sales546.89258.562,486.1080.08
Price / CashN/A36.4636.1431.61
Price / Book4.965.795.434.60
Net Income-$44.60M$130.57M$106.05M$214.07M
7 Day Performance0.04%-2.46%-1.42%-1.11%
1 Month Performance26.67%1.51%2.67%3.17%
1 Year Performance309.27%-6.56%3.35%7.84%

Corbus Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CELC
Celcuity
2.0213 of 5 stars
$16.51
-1.7%
$29.50
+78.7%
+42.2%$515.61MN/A-5.9455
STTK
Shattuck Labs
2.346 of 5 stars
$7.72
+3.6%
$20.00
+159.1%
+155.6%$367.09M$1.66M-4.0075
SLDB
Solid Biosciences
4.0746 of 5 stars
$8.51
-6.7%
$17.50
+105.6%
+29.6%$326.61M$8.09M-2.1688Analyst Revision
IMMP
Immutep
1.0251 of 5 stars
$3.23
+4.2%
$8.50
+163.2%
+15.9%$284.01M$3.50M0.002,021
DNTH
Dianthus Therapeutics
0.8865 of 5 stars
$24.57
-3.5%
$42.83
+74.3%
N/A$721.13M$2.83M-4.2153
COGT
Cogent Biosciences
2.1576 of 5 stars
$7.92
+1.0%
$14.67
+85.2%
-29.1%$757.23MN/A-3.19164Analyst Forecast
News Coverage
WVE
Wave Life Sciences
4.559 of 5 stars
$6.32
-0.9%
$10.25
+62.2%
+73.3%$773.95M$113.31M-12.15266
ACRV
Acrivon Therapeutics
3.116 of 5 stars
$8.21
-4.0%
$22.88
+178.6%
-35.6%$185.87MN/A-2.8558
STOK
Stoke Therapeutics
3.8758 of 5 stars
$15.35
-4.7%
$20.57
+34.0%
+30.6%$800.04M$8.78M-6.37110
PRQR
ProQR Therapeutics
2.4651 of 5 stars
$1.90
-1.0%
$3.38
+77.6%
+6.8%$154.58M$7.05M-5.13156Gap Up

Related Companies and Tools

This page (NASDAQ:CRBP) was last updated on 5/25/2024 by MarketBeat.com Staff

From Our Partners